Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA: First Adapted COVID-19 Vaccines Expected In September

Data Still Awaited On Valneva Vaccine & Molnupiravir

Executive Summary

As work continues on vaccines adapted to tackle variants of SARS-CoV-2, the EU regulator says the decision-making on such products should take place at a global level.

You may also be interested in...

Coronavirus Notebook: New EU Body To Advise On Future Pandemic Actions, Valneva Awaits EMA Verdict On Vaccine Candidate

French health tech firm NOVA has produced a model for assessing the impact of non-pharmaceutical COVID-19 interventions on clinical trials of respiratory tract drugs, and Moderna’s Spikevax has been OKd for younger children in Great Britain.

Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial

RedHill’s opaganib has shown “potent inhibition” of the Omicron variant in early studies, while the EMA has found no links between the mRNA vaccines and autoimmune hepatitis.

Coronavirus Notebook: EMA Starts Review Of HIPRA’s COVID-19 Vaccine, Moderna To Set Up Australian mRNA Plant

There is no shortage of news relating to potential new COVID-19 treatments and vaccines. Among other things, zapnometinib, an antiviral compound being developed by German firm Atriva, has shown strong efficacy against Omicron in a Phase I study. Also, Sweden’s ISR and Iconovo have expanded their collaboration deal to accelerate the development of an inhaled COVID-19 vaccine.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts